GSK's anticancer Tykerb among new Japanese recommendations
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's Tykerb (lapatinib) has been recommended for approval in Japan, for use in combination with Chugai/Roche's chemotherapeutic agent Xeloda (capecitabine).